Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Trial Profile

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Jan 2019

At a glance

  • Drugs Enzalutamide (Primary) ; Talazoparib (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms TALAPRO-2
  • Sponsors Pfizer
  • Most Recent Events

    • 02 Jan 2019 Planned primary completion date changed from 1 Aug 2022 to 1 Sep 2022.
    • 28 Nov 2018 Planned End Date changed from 15 Nov 2024 to 1 Nov 2024.
    • 28 Nov 2018 Planned primary completion date changed from 17 Aug 2022 to 1 Aug 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top